natgillin/translations-raw huggingface dataset:
Of the circulating metabolites, the majority are glucuronide conjugates of posaconazole with only minor amounts of oxidative (CYP450 mediated) metabolites observed. 
Većina metabolita u cirkulaciji su glukuronidni konjugati posakonazola, a opažene su samo manje količine oksidativnih metabolita (posredstvom enzima CYP450).
Posaconazole should be used with caution in patients with hepatic impairment due to limited clinical experience and the possibility that posaconazole plasma levels may be higher in these patients (see sections 4.2 and 5.2). 
Posakonazol se mora primjenjivati uz oprez u bolesnika s oštećenjem funkcije jetre zbog ograničenog kliničkog iskustva i mogućnosti većih koncentracija posakonazola u plazmi u tih bolesnika (vidjeti dijelove 4.2 i 5.2).
Patients were enrolled in a non-comparative pharmacokinetic and safety trial of posaconazole tablets when given as antifungal prophylaxis. 
Bolesnici su bili uključeni u nekomparativno ispitivanje farmakokinetike i sigurnosti tableta posakonazola kad se posakonazol davao kao antimikotička profilaksa.
The excretion of posaconazole in human breast milk has not been investigated. 
Izlučivanje posakonazola u majčino mlijeko u ljudi nije se ispitivalo.
Administration of other azoles has been associated with increases in digoxin levels. 
Primjena drugih azola povezuje se s povećanjem koncentracije digoksina.
If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended. 
Ako je istodobna primjena neophodna, preporučuje se pomno nadziranje zbog mogućih probojnih gljivičnih infekcija.
Treatment with these HMG-CoA reductase inhibitors should be discontinued during treatment with posaconazole as increased levels have been associated with rhabdomyolysis (see section 4.3). 
Liječenje inhibitorima HMG-CoA reduktaze mora se prekinuti tijekom liječenja posakonazolom jer se povećane koncentracije povezuju s rabdomiolizom (vidjeti dio 4.3).
If you are not sure, talk to your doctor or pharmacist before taking this medicine. 
obratite se svom liječniku ili ljekarniku prije uzimanja ovog lijeka.
Posaconazole increased the Cmax and AUC of rifabutin by 31% and 72%, respectively. 
Rifabutin Posakonazol je povećao Cmax rifabutina za 31%, a AUC za 72%.
In a study in healthy volunteers posaconazole oral suspension (200 mg once daily for 10 days) increased the exposure (AUC) of intravenous midazolam (0.05 mg/kg) by 83%. 
U ispitivanju u zdravih dobrovoljaca oralna suspenzija posakonazola (200 mg jedanput na dan tijekom 10 dana) povećala je izloženost (AUC) intravenski primijenjenog midazolama (0,05 mg/kg) za 83%.
There is no special treatment available in the case of overdose with posaconazole. 
Nema posebnog liječenja u slučaju predoziranja posakonazolom.
Posaconazole was not genotoxic in in vitro and in vivo studies. 
Posakonazol nije pokazao genotoksične učinke u ispitivanjima in vitro i in vivo.
Posaconazole is metabolised via UDP glucuronidation (phase 2 enzymes) and is a substrate for pglycoprotein (P-gp) efflux in vitro. 
Posakonazol se metabolizira UDP-glukuronidacijom (enzimima faze 2) i supstrat je efluksa preko P-glikoproteina (P-gp) in vitro.
fluconazole, itraconazole or voriconazole. 
itrakonazol ili vorikonazol;
There is no information regarding cross-sensitivity between posaconazole and other azole antifungal agents. 
Nema podataka o križnoj preosjetljivosti između posakonazola i drugih azolnih antimikotika.
altered medicine levels, blood phosphorus decreased, chest x-ray abnormal * Based on adverse reactions observed with the oral suspension, gastro-resistant tablets, and concentrate for solution for infusion. 
promjene u koncentraciji lijeka, snižene razine fosfora u krvi, odstupanja u rendgenskom nalazu prsnog koša * Na temelju nuspojava primijećenih kod primjene oralne suspenzije, želučanootpornih tableta i koncentrata za otopinu za infuziju.
mouth ulceration, alopecia, dermatitis, erythema, petechiae 
ulceracije u ustima, alopecija, dermatitis, eritem, petehije
In subjects with severe renal impairment (n=6, Clcr< 20 mL/min/1.73 m2), the AUC of posaconazole was highly variable [> 96% CV (coefficient of variance)] compared to other renal groups [< 40% CV]. 
U ispitanika s teškim oštećenjem funkcije bubrega (n=6, CIcr <20 ml/min/1,73 m2), AUC posakonazola jako je varirao [>96 % CV (koeficijent varijabilnosti)] u usporedbi s drugim kategorijama funkcije bubrega [<40 % CV].
An effect of renal impairment on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended (see section 5.2). 
Ne očekuje se da će oštećenje funkcije bubrega utjecati na farmakokinetiku posakonazola te se ne preporučuje prilagođavanje doze (vidjeti dio 5.2).
Neutropenia 
neutropenija
During clinical trials, patients who received posaconazole oral suspension doses up to 1,600 mg/day experienced no different adverse reactions from those reported with patients at the lower doses. 
U kliničkim ispitivanjima, bolesnici koji su primali oralnu suspenziju posakonazola u dozama do 1600 mg na dan nisu imali drugačije nuspojave od onih prijavljenih u bolesnika koji su primali niže doze lijeka.
Wessling Hungary Kft. Anonymus ut 6. 
Wessling Hungary Kft.
Discontinuation of Posaconazole Accord should be considered if clinical signs and symptoms are consistent with development of liver disease. 
Potrebno je razmotriti mogućnost prekida primjene lijeka Posakonazol Accord u slučaju nastupa kliničkih znakova i simptoma koji ukazuju na razvoj bolesti jetre.
Posaconazole is an inhibitor of CYP3A4 and should only be used under specific circumstances during treatment with other medicinal products that are metabolised by CYP3A4 (see section 4.5). 
Posakonazol je inhibitor CYP3A4 i samo se u posebnim okolnostima smije primjenjivati tijekom liječenja drugim lijekovima koji se metaboliziraju putem CYP3A4 (vidjeti dio 4.5).
Breast-feeding must be stopped on initiation of treatment with posaconazole. 
Dojenje se mora prekinuti kada započne liječenje posakonazolom.
When initiating posaconazole treatment in patients already receiving tacrolimus, the dose of tacrolimus should be reduced (e.g. to about one third of the current dose). 
Kada se započinje liječenje posakonazolom u bolesnika koji već primaju takrolimus, dozu takrolimusa treba smanjiti (npr. na otprilike jednu trećinu dotadašnje doze).
Vinca alkaloids 
Vinka alkaloidi
Rifabutin (300 mg once a day) decreased the Cmax (maximum plasma concentration) and AUC (area under the plasma concentration time curve) of posaconazole to 57% and 51%, respectively. 
Rifabutin (300 mg jedanput na dan) je snizio Cmax (maksimalna koncentracija u plazmi) posakonazola na 57%, a AUC (površina ispod krivulje koncentracija-vrijeme) na 51%.
Several of the interaction studies were conducted in healthy volunteers in whom a higher exposure to posaconazole occurs compared to patients administered the same dose. 
Provedeno je nekoliko ispitivanja interakcija sa zdravim dobrovoljcima, u kojih je izloženost posakonazolu bila veća nego u bolesnika koji su primili jednaku dozu lijeka.
Co-administration with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine since this may result in increased plasma concentrations of these medicinal products, leading to QTc prolongation and rare occurrences of torsades de pointes (see sections 4.4 and 4.5). 
Istodobna primjena supstrata enzima CYP3A4 terfenadina, astemizola, cisaprida, pimozida, halofantrina ili kinidina, jer može doći do povećanja koncentracije ovih lijekova u plazmi te time do produljenja QTc intervala, a u rijetkim slučajevima i do pojave torsade de pointes (vidjeti dijelove 4.4 i 4.5).
In Table 3 a comparison is shown of exposure (Cav) after administration of posaconazole tablet and posaconazole oral suspension at therapeutic doses in patients depicted as quartile analysis. 
Tablica 3 prikazuje usporedbu izloženosti (Cav) nakon primjene terapijskih doza tableta posakonazola i oralne suspenzije posakonazola u bolesnika odabranih za analizu kvartila.
adrenal insufficiency, blood gonadotropin decreased 
insuficijencija nadbubrežne žlijezde, snižene vrijednosti gonadotropina u krvi
Co-administration of posaconazole and ergot alkaloids is contraindicated (see section 4.3). 
Istodobna primjena posakonazola i ergot alkaloida je kontraindicirana (vidjeti dio 4.3).
Do not breast-feed while taking Posaconazole Accord. 
Nemojte dojiti dok uzimate Posakonazol Accord.
Posaconazole increased Cmax and AUC of tacrolimus (0.05 mg/kg body weight single dose) by 121% and 358%, respectively. 
Posakonazol je povećao Cmax takrolimusa (primijenjenog u jednokratnoj dozi od 0,05 mg/kg tjelesne mase) za 121%, a AUC za 358%.
QTc prolongation 
Produljenje QTc-intervala
convulsions, neuropathy, hypoaesthesia, tremor, aphasia, insomnia 
konvulzije, neuropatija, hipoestezija, tremor, afazija, nesanica
As a result, sirolimus trough concentrations that fall within the usual therapeutic range may result in sub-therapeutic levels. 
Kao posljedica toga može se dogoditi da najniža koncentracija sirolimusa, koja je inače unutar uobičajenih terapijskih vrijednosti, padne ispod terapijske razine.
Posaconazole may increase the plasma concentrations of vinca alkaloids which may lead to neurotoxicity and other serious adverse reactions. 
Posakonazol može povećati koncentraciju vinka alkaloida u plazmi, što može dovesti do neurotoksičnosti i drugih ozbiljnih nuspojava.
hypersensitivity reaction 
reakcije preosjetljivosti
300 mg once daily (Day 1 300 mg twice daily)* 
300 mg jedanput na dan (1. dan 300 mg dvaput na dan)*
No dosage adjustment of posaconazole tablets is required when posaconazole tablets are concomitantly used with antacids, H2-receptor antagonists and proton pump inhibitors. 
Nije potrebna prilagodba doze tableta posakonazola kad se tablete posakonazola primjenjuju istodobno s antacidima, antagonistima H2receptora i inhibitorima protonske pumpe.
Concomitant use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole). 
Istodobnu primjenu posakonazola i rifabutina treba izbjegavati, osim ako moguća korist za bolesnika nadilazi rizik liječenja (o učinku rifabutina na koncentraciju posakonazola u plazmi vidjeti također u gornjem tekstu).
hypotension, vasculitis 
hipotenzija, vaskulitis
There are currently insufficient data to set clinical breakpoints for Aspergillus spp. 
Trenutno nema dovoljno podataka prema kojima bi se odredile kliničke granične vrijednosti za vrstu roda Aspergillus.
Co-administration of posaconazole with CYP3A4 substrates may result in large increases in exposure to CYP3A4 substrates as exemplified by the effects on tacrolimus, sirolimus, atazanavir and midazolam below. 
Istodobna primjena posakonazola i supstrata CYP3A4 može uzrokovati povećanu izloženost supstratima CYP3A4, što se vidi iz niže navedenih primjera učinaka na takrolimus, sirolimus, atazanavir i midazolam.
Terfenadine, astemizole, cisapride, pimozide, halofantrine and quinidine (CYP3A4 substrates) Co-administration of posaconazole and terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine is contraindicated. 
Terfenadin, astemizol, cisaprid, pimozid, halofantrin i kinidin (supstrati CYP3A4) Istodobna primjena posakonazola i terfenadina, astemizola, cisaprida, pimozida, halofantrina ili kinidina je kontraindicirana.
- if you are taking: terfenadine, astemizole, cisapride, pimozide, halofantrine, quinidine, any medicines that contain “ergot alkaloids” such as ergotamine or dihydroergotamine, or a “statin” such as simvastatin, atorvastatin or lovastatin 
- ako uzimate: terfenadin, astemizol, cisaprid, pimozid, halofantrin, kinidin, bilo koji lijek koji sadrži ergot alkaloide kao što su ergotamin ili dihidroergotamin ili statine kao što su simvastatin, atorvastatin ili lovastatin.
Posaconazole may substantially increase plasma levels of HMG-CoA reductase inhibitors that are metabolised by CYP3A4. 
Posakonazol može znatno povećati koncentraciju inhibitora HMG-CoA reduktaze u plazmi koji se metaboliziraju putem CYP3A4.
Posaconazole Accord must not be administered with medicinal products that are substrates for CYP3A4 and are known to prolong the QTc interval (see sections 4.3 and 4.5). 
Posakonazol Accord ne smije se primjenjivati s lijekovima koji su supstrati enzima CYP3A4 i za koje je poznato da produljuju QTc-interval (vidjeti dijelove 4.3 i 4.5).
This belongs to a group of medicines called “antifungals”. 
On pripada skupini lijekova koji se zovu
Posaconazole tablets 
Tablete posakonazola
The other ingredients are: Methacrylic acid-ethyl acrylate copolymer (1:1), triethyl citrate (E1505), xylitol (E967), hydroxypropyl cellulose (E463), propyl gallate (E310), cellulose microcrystalline (E460), silica colloidal anhydrous, croscarmellose sodium, sodium stearyl fumarate, polyvinyl alcohol, titanium dioxide (E171), macrogol, talc (E553b), iron oxide yellow (E172). 
Drugi sastojci su: metakrilatna kiselina/etilakrilat kopolimer 1:1, trietilcitrat (E1505), ksilitol (E967) hidroksipropilceluloza (E463), propilgalat (E310) celuloza, mikrokristalična (E460), silicijev dioksid, koloidni, bezvodni, karmelozanatrij, umrežena, natrijev stearilfumarat, (poli)vinilni alkohol, titanijev dioksid (E171), makrogol, talk (E553b), željezov oksid, žuti (E172)
HMG-CoA reductase inhibitors metabolised through CYP3A4 (e.g. simvastatin, lovastatin, and atorvastatin) 
Inhibitori HMG-CoA reduktaze koji se metaboliziraju putem CYP3A4 (npr. simvastatin, lovastatin i atorvastatin)
Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma concentrations. 
Fosamprenavir Kombinacija fosamprenavira i posakonazola može dovesti do sniženja koncentracije posakonazola u plazmi.
Co-administration with ergot alkaloids (see section 4.5). 
Istodobna primjena s ergot alkaloidima (vidjeti dio 4.5).
There was a slight decrease (16%) in the AUC and Cmax of posaconazole oral suspension in Black subjects relative to Caucasian subjects. 
Zabilježen je lagani pad (16 %) AUC-a i Cmax oralne suspenzije posakonazola u ispitanika crne rase u odnosu na ispitanike bijele rase.
Following single-dose administration of posaconazole oral suspension, there was no effect of mild and moderate renal impairment (n=18, Cl cr ≥ 20 mL/min/1.73 m2) on posaconazole pharmacokinetics; therefore, no dose adjustment is required. 
Nakon primjene jednokratne doze oralne suspenzije posakonazola, blago ili umjereno oštećenje funkcije bubrega (n=18, CIcr ≥20 ml/min/1,73 m2) nije utjecalo na farmakokinetiku posakonazola, pa nije potrebna prilagodba doze.
Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02AC04 
Farmakoterapijska skupina: antimikotici za sistemsku primjenu, derivati triazola, ATK oznaka:
Clinical isolates with decreased susceptibility to posaconazole have been identified. 
Pronađeni su klinički izolati sa smanjenom osjetljivošću na posakonazol.
P-Value 
Kontrolna skupinaa p-vrijednost
No effects on electrocardiograms, including QT and QTc intervals, were seen in a repeat dose safety pharmacology study in monkeys at maximal plasma concentrations 8.5-fold greater than the concentrations obtained at therapeutic doses in humans. 
U farmakološkom ispitivanju sigurnosti ponovljenih doza u majmuna nisu uočeni učinci na elektrokardiograme, uključujući QT i QTc-intervale, pri maksimalnim koncentracijama u plazmi koje su bile 8,5 puta veće od koncentracije koja se postiže terapijskim dozama u ljudi.
back pain, neck pain, musculoskeletal pain, pain in extremity 
bol u leđima, bol u vratu, mišićno-koštana bol, bol u ekstremitetima
If you develop severe diarrhoea or vomiting (being sick) while taking Posaconazole Accord, talk to your doctor, pharmacist or nurse straight away, as this may stop it from working properly. 
Ako dobijete teški proljev ili povraćate dok uzimate Posakonazol Accord, odmah se obratite svom liječniku, ljekarniku ili medicinskoj sestri, jer to može narušiti ispravno djelovanje lijeka Posakonazol Accord.
Serial PK samples were collected on Day 1 and at steady-state on Day 8 for all Part 1 subjects and a subset of Part 2 subjects. 
Serijski uzorci za procjenu farmakokinetike prikupljeni su prvog dana i u stanju dinamičke ravnoteže osmog dana kod svih ispitanika u Dijelu 1 te podskupini ispitanika u Dijelu 2.
Following a single dose administration of 300 mg posaconazole tablets after a high fat meal to healthy volunteers, the AUC0-72 hours and Cmax were higher compared to administration under fasted condition (51% and 16% for AUC0-72 hours and Cmax respectively). 
Nakon jednokratne primjene tableta posakonazola u dozi od 300 mg nakon obroka bogatog mastima u zdravih dobrovoljaca, AUC0-72 h i Cmax bili su viši u usporedbi s primjenom natašte (51 % za AUC0-72 h te 16 % za Cmax).
You may feel dizzy, sleepy, or have blurred vision while taking Posaconazole Accord, which may affect your ability to drive or use tools or machines. 
Dok uzimate Posakonazol Accord, možete osjetiti omaglicu, pospanost ili imati zamućen vid, što može utjecati na Vašu sposobnost upravljanja vozilima i rada sa strojevima.
Posaconazole had no effect on fertility of male rats at doses up to 180 mg/kg (3.4 times the 300 mg tablet based on steady-state plasma concentrations in patients) or female rats at a dose up to 45 mg/kg (2.6 times the 300 mg tablet based on steady-state plasma concentrations in patients). 
U štakora, posakonazol nije imao učinak na plodnost mužjaka pri dozama do najviše 180 mg/kg (što je 3,4 puta više od doziranja 300 mg u tableti, izračunato na temelju koncentracije u plazmi u stanju dinamičke ravnoteže u bolesnika) niti na plodnost ženki pri dozi do najviše 45 mg/kg (što je 2,6 puta više od doziranja 300 mg u tableti, izračunato na temelju koncentracije u plazmi u stanju dinamičke ravnoteže u bolesnika).
Posaconazole after administration of the tablets, is slowly eliminated with a mean half-life (t½) of 29 hours (range 26 to 31 hours) and a mean apparent clearance ranging from 7.5 to 11 L/hr. 
Nakon primjene tableta, posakonazol se sporo eliminira uz srednju vrijednost poluvremena eliminacije (t½) od 29 sati (raspon: 26 do 31 sat) i srednju vrijednost prividnog klirensa u rasponu od 7,5 do 11 l/h.
World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, Barcelona, 
World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, Barcelona, 08039 Barcelona, Španjolska
Proportion (%) of patients with proven/probable IFIs On-treatment periodb d 
Udio (%) bolesnika s dokazanom/vjerojatnom IGI
If you become pregnant while you are taking Posaconazole Accord, contact your doctor straight away. 
Ako zatrudnite tijekom liječenja lijekom Posakonazol Accord, odmah se obratite svom liječniku.
In heart transplant patients on stable doses of ciclosporin, posaconazole oral suspension 200 mg once daily increased ciclosporin concentrations requiring dose reductions. 
U bolesnika koji su nakon transplantacije srca primali stabilne doze ciklosporina, oralna suspenzija posakonazola u dozi od 200 mg jedanput na dan povećala je koncentraciju ciklosporina, zbog čega se morala smanjiti doza toga lijeka.
11 of 24 patients who had proven or probable fusariosis were successfully treated with posaconazole oral suspension 800 mg/day in divided doses for a median of 124 days and up to 212 days. 
Jedanaest od 24 bolesnika koji su imali dokazanu ili vjerojatnu fuzariozu uspješno je liječeno oralnom suspenzijom posakonazola od 800 mg na dan u podijeljenim dozama tijekom medijana od 124 dana, a najdulje 212 dana.
Posaconazole concentrations may be significantly lowered in combination; therefore, concomitant use with posaconazole should be avoided unless the benefit to the patient outweighs the risk (see section 4.5). 
Koncentracija posakonazola može biti značajno snižena u kombinaciji s ovim lijekovima pa istodobnu primjenu treba izbjegavati, osim ako moguća korist za bolesnika nadilazi rizik liječenja (vidjeti dio 4.5).
Subjects achieved a mean predicted Cav at steady state of 1,970 ng/mL. 
Ispitanici su postigli srednju vrijednost predviđenog Cav-a u stanju dinamičke ravnoteže od 1970 ng/ml.
Overall Response Success by Species All mycologically confirmed Aspergillus spp.1 
Uspjeh prema vrstama uzročnika Sve mikološki potvrđene vrste roda Aspergillus spp.1 A. fumigatus A. flavus
Caution is advised during coadministration of posaconazole with CYP3A4 substrates administered intravenously and the dose of the CYP3A4 substrate may need to be reduced. 
Savjetuje se oprez tijekom istodobne primjene posakonazola i supstrata CYP3A4 koji se primjenjuju intravenski, a možda će biti potrebno sniziti dozu supstrata CYP3A4.
hyperglycaemia, hypoglycaemia 
hiperglikemija, hipoglikemija
Accidental overdose was noted in one patient who took posaconazole oral suspension 1,200 mg twice a day for 3 days. 
Slučajno predoziranje zabilježeno je u jednog bolesnika koji je tijekom 3 dana uzimao oralnu suspenziju posakonazola u dozi od 1200 mg dvaput na dan.
Two different dosing groups were evaluated: 200 mg twice daily on Day 1, followed by 200 mg once daily thereafter (Part IA) and 300 mg twice daily on Day 1, followed by 300 mg once daily thereafter (Part 1B and Part 2). 
Bile su procijenjene dvije skupine koje su primale različite doze: 200 mg dvaput na dan prvog dana te nakon toga 200 mg jedanput na dan (Dio IA) i 300 mg dvaput na dan prvog dana te nakon toga 300 mg jedanput na dan (Dio 1B i Dio 2).
Dose adjustment of benzodiazepines metabolised by CYP3A4 should be considered (see section 4.5). 
Treba razmotriti prilagodbu doze benzodiazepina koji se metaboliziraju putem CYP3A4 (vidjeti dio 4.5).
The most frequently reported serious related adverse reactions included nausea, vomiting, diarrhoea, pyrexia, and increased bilirubin. 
Najčešće prijavljene ozbiljne nuspojave povezane s primjenom lijeka uključivale su mučninu, povraćanje, proljev, pireksiju te povišene razine bilirubina.
Due to the risk of prolonged sedation and possible respiratory depression co-administration of posaconazole with any benzodiazepines metabolised by CYP3A4 (e.g. midazolam, triazolam, alprazolam) should only be considered if clearly necessary. 
Zbog rizika od produljene sedacije i moguće depresije dišnog sustava, istodobna primjena posakonazola s bilo kojim benzodiazepinom koji se metabolizira putem CYP3A4 (npr. midazolamom, triazolamom, alprazolamom) smije se razmotriti samo u slučaju jasne potrebe.
If you forget to take Posaconazole Accord - If you forget a dose, take it as soon as you remember it. - However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. 
Ako ste zaboravili uzeti Posakonazol Accord - Ako ste zaboravili uzeti dozu, uzmite ju čim se sjetite.
Reproduction, peri- and postnatal development studies were conducted in rats. 
Provedena su ispitivanja utjecaja posakonazola na reprodukciju, perinatalni i postnatalni razvoj u štakora.
9 of 11 patients were successfully treated with posaconazole oral suspension 800 mg/day in divided doses for a median of 268 days and up to 377 days. 
Devet od 11 bolesnika uspješno je liječeno oralnom suspenzijom posakonazola od 800 mg na dan u podijeljenim dozama tijekom medijana od 268 dana, a najdulje 377 dana.
The ECOFF values for posaconazole, which distinguish the wild type population from isolates with acquired resistance, have been determined by EUCAST methodology. 
Epidemiological Cut-off, ECOFF) za vrste roda Aspergillus ECOFF vrijednosti za posakonazol prema kojima se razlikuje divlji tip populacije od izolata sa stečenom rezistencijom određene su metodologijom propisanom od strane Europskog odbora za testiranje osjetljivosti na antimikrobne lijekove (engl.
The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with ritonavir is unknown. 
Nije poznat učinak posakonazola na koncentraciju fosamprenavira kada se fosamprenavir primjenjuje s ritonavirom.
torsade de pointes, sudden death, ventricular tachycardia, cardio-respiratory arrest, cardiac failure, myocardial infarction 
torsade de pointes, iznenadna smrt, ventrikularna tahikardija, kardiorespiratorni arest, zatajenje srca, infarkt miokarda